SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host investor meetings at the following investor conferences. 

Details on the presentations are as follows:

Event:

Piper Sandler 36th Annual Healthcare Conference

Presenter:

Nicole LaBrosse, Chief Financial Officer

Format:

Fireside Chat and 1x1 Meetings

Presentation Date:

Wednesday, December 4, 2024

Presentation Time:

10:30am PT / 1:30pm ET

Location:

New York, NY

SAN DIEGO, 22. November 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) („Halozyme" oder das „Unternehmen") hat heute bekannt gegeben, dass es sein unverbindliches Angebot zum Zusammenschluss mit der Evotec SE (NASDAQ: EVO) („Evotec") für einen Barpreis in Höhe von 11,00 € pro Aktie zurückgenommen hat. Das Angebot entsprach einem Eigenkapitalwert auf vollständig verwässerter Basis von 2,0 Milliarden €.

Helen Torley, Präsidentin und Vorstandsvorsitzende von Halozyme, gab folgende Erklärung ab:

SAN DIEGO, Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion.  

Helen Torley, president and chief executive officer of Halozyme, shared the following statement:

"We continue to believe that a combination of Halozyme and Evotec would create a leading, differentiated, global pharma services company, benefitting shareholders, patients and employees. However, to date, Evotec has been unwilling to engage with us to explore a potential combination and a company spokesperson has publicly commented that its goal is to remain an independent company. As a result, we are withdrawing our proposal to acquire Evotec for €11.00 per share in cash.

Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologies

Would meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyond

All-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close

SAN DIEGO, Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. In a presentation posted on its investor relations website, Halozyme highlights how its proposed combination with Evotec would create a leading global innovative pharma services company that would deliver significant value to all stakeholders.

Halozyme Therapeutics, Inc. 

Ein Zusammenschluss würde ein globales und innovatives Dienstleistungsunternehmen schaffen – mit einem einzigartigen Spektrum unterschiedlichster Technologien, einer vielfältigen Produktpipeline und einem branchenführenden Team

SAN DIEGO, 14. November 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) („Halozyme" oder das „Unternehmen") bestätigt, dass es dem Vorstand und Aufsichtsrat der Evotec SE (NASDAQ: EVO) („Evotec") ein bestimmten Bedingungen unterliegendes Angebot zur Übernahme von Evotec für einen Barpreis in Höhe von 11,00 € pro Aktie unterbreitet hat. Dies entspricht einem Eigenkapitalwert auf vollständig verwässerter Basis von 2,0 Mrd. €. Das Angebot entspricht einem Aufschlag von 109 % auf den unbeeinflussten Aktienkurs von Evotec vom 15. Oktober 2024, dem Tag vor dem ersten Erwerb von Evotec-Aktien durch Triton Partners, und einem Aufschlag von 77 % auf den volumengewichteten Durchschnittskurs der Evotec-Aktie in den drei vorausgegangenen Monaten.

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team

SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) ("Evotec") to acquire Evotec for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. The proposal represents a premium of 109% to Evotec's undisturbed share price on October 15, 2024, the day prior to Triton Partners' initial accumulation of Evotec shares, and a premium of 77% to Evotec's last three-month volume weighted average price on October 15, 2024.

Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million

Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million

GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.271

Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595-$625 million, Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of $4.00-$4.20, Representing YOY Growth of 44%-52%

Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO® and SC through 2032

Reiterates 2024 Royalty Revenue Guidance of $520-555 million and Expectations to Generate >$1 billion in 2027

Conference Call Scheduled Today, Thursday, October 24 at 5:30am PT/8:30am ET

SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update following a decision by the Opposition Division of the European Patent Office ("EPO") to revoke one of the Janssen Biotech, Inc. (Janssen) co-formulation patents for DARZALEX® (daratumumab) SC (Patent EP 3827845).

SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024, following the close of trading.

Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813747.

A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.